Persbericht Biocartis Group NV: Biocartis Group NV brengt een update rond de publicatie van haar jaarverslag en de jaarlijkse algemene vergadering
May 09, 2024 01:00 ET
|
Biocartis Group NV
BIOCARTIS GROUP NV (Euronext Brussels: BCART) PERSBERICHT - GEREGULEERDE INFORMATIE - 09 mei 2024, 07:00 CEST Biocartis Group NV brengt een update rond de publicatie van haar jaarverslag en de...
Press release Biocartis Group NV: Biocartis Group NV provides an update regarding the publication of its annual report and the annual meeting
May 09, 2024 01:00 ET
|
Biocartis Group NV
BIOCARTIS GROUP NV (Euronext Brussels: BCART) PRESS RELEASE - REGULATED INFORMATION - 09 May 2024, 07:00 CEST Biocartis Group NV provides an update regarding the publication of its annual report and...
In Vitro Diagnostics (IVD) Market Size to Reach USD 202.9 Billion By 2032, at 7.4% CAGR: Dimension Market Research
May 08, 2024 12:34 ET
|
Dimension Market Research
New York, May 08, 2024 (GLOBE NEWSWIRE) -- Overview The Global In Vitro Diagnostics (IVD) market was valued at USD 106.9 Billion in 2023 which is further expected to reach USD 202.9 Billion in...
Global Rare Disease Diagnostics Market Insights 2024-2030: Rising Use in Translational & Genomic Research Driving the Industry to $8.23 Billion by 2030
May 08, 2024 05:07 ET
|
Research and Markets
Dublin, May 08, 2024 (GLOBE NEWSWIRE) -- The "Global Rare Disease Diagnostics Market by Component (Consumable & Assay Kit, Diagnostic Instrument), Technology (Array Technology, Next Generation...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against QuidelOrtho, Perion, Doximity, and Sharecare and Encourages Investors to Contact the Firm
May 07, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of...
Diagnostic Collaboration, Development, Research and Licensing Deals Analysis Report 2024 with Directory of 1640 Agreements Signed Since 2019
May 07, 2024 06:26 ET
|
Research and Markets
Dublin, May 07, 2024 (GLOBE NEWSWIRE) -- The "Diagnostic Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offering.Diagnostic Collaboration and...
QDEL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that QuidelOrtho Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
May 06, 2024 04:00 ET
|
Bronstein, Gewirtz & Grossman, LLC
NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been...
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle East and North Africa (MEA) Region
May 06, 2024 01:00 ET
|
Biocartis NV
PRESS RELEASE - 06/05/2024, 07:00 CEST Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle East and North Africa (MEA) Region Biocartis (Mechelen,...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ocugen, QuidelOrtho, Sharecare, and GoodRx and Encourages Investors to Contact the Firm
May 02, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of...
New YPrime Report Highlights eCOA's Impact on CNS Trials
May 01, 2024 08:00 ET
|
Y-Prime, LLC
YPrime has released a new report, Insights into CNS Clinical Trials, which demonstrates to sponsors how eCOA can help streamline CNS research.